FinancingCompany-reported
What was reported
HOUSTON, TX, May 19, 2026, Nexalin Technology, Inc. (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its acquisition of PONM, Inc. (“PONM”) from GreenLight Ventures, LLC (“GreenLight”). PONM is the digital health platform supporting Nexalin’s HALO™ Clarity program and Nexalin NeuroCare™ virtual clinic.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 19, 2026 · Open the source ↗
What the evidence supports
Nexalin Technology told the SEC (Form 8-K, Item 1.01) that it entered into a financing arrangement or sold its securities. The filing gives May 14, 2026 as the date of the earliest event reported. The company also furnished a press release, which is its own account rather than a regulatory statement.
What remains unknown
How much money will actually be raised or drawn, at what final price, and how it will be used beyond what the company stated. Stated amounts can be maximums or targets rather than money already received.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineNexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal TrialU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 19, 2026 · Open the source ↗
Press release lead paragraphHOUSTON, TX, May 19, 2026, Nexalin Technology, Inc. (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its acquisition of PONM, Inc. (“PONM”) from GreenLight Ventures, LLC (“GreenLight”). PONM is the digital health platform supporting Nexalin’s HALO™ Clarity program and Nexalin NeuroCare™ virtual clinic.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 19, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.